# Nada BoÅ¾ina

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/486173/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 77<br>papers | 1,523<br>citations | 331670<br>21<br>h-index | 345221<br>36<br>g-index |
| 79<br>all docs | 79<br>docs citations | 79<br>times ranked | 2184<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidineâ€based protocols. British Journal of Clinical Pharmacology, 2022, 88, 2190-2202. | 2.4 | 8 |
| 2 | Rapid clearance of tacrolimus blood concentration triggered by variant pharmacogenes. Journal of Clinical Pharmacy and Therapeutics, 2022, , . | 1.5 | 2 |
| 3 | ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110042. | 4.8 | 9 |
| 4 | Association of methylenetetrahydrofolate reductase C677T CT gene polymorphism with a non-dipping blood pressure pattern in morbidly obese patients. Cardiologia Croatica, 2021, 16, 38-39. | 0.0 | 0 |
| 5 | Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review. Arhiv Za Higijenu Rada I Toksikologiju, 2021, 72, 114-128. | 0.7 | 2 |
| 6 | Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a caseâ€“control study. European Journal of Clinical Pharmacology, 2021, , 1. | 1.9 | 7 |
| 7 | Association of polygenic risk scores, traumatic life events and coping strategies with war-related PTSD diagnosis and symptom severity in the South Eastern Europe (SEE)-PTSD cohort. Journal of Neural Transmission, 2021, , 1. | 2.8 | 3 |
| 8 | Impact of Continuous P2Y12 Inhibition Tailoring in Acute Coronary Syndrome and Genetically Impaired Clopidogrel Absorption. Journal of Cardiovascular Pharmacology, 2020, 75, 174-179. | 1.9 | 3 |
| 9 | Pharmacogenetics and statin-related myopathy: what do we know?. Pharmacogenomics, 2020, 21, 821-825. | 1.3 | 6 |
| 10 | Severe hyperglycaemia following pazopanib treatment: The role of drugâ€drugâ€gene interactions in a patient with metastatic renal cell carcinomaâ€”A case report. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 628-631. | 1.5 | 3 |
| 11 | Implementation of pharmacogenomics in product information. Pharmacogenomics, 2020, 21, 443-448. | 1.3 | 3 |
| 12 | Association of HSPA1B genotypes with psychopathology and neurocognition in patients with the first episode of psychosis: a longitudinal 18-month follow-up study. Pharmacogenomics Journal, 2020, 20, 638-646. | 2.0 | 4 |
| 13 | REMISSION IS NOT ASSOCIATED WITH DRD2 RS1800497 AND DAT1 RS28363170 GENETIC VARIANTS IN MALE SCHIZOPHRENIC PATIENTS AFTER 6-MONTHS MONOTHERAPY WITH OLANZAPINE. Psychiatria Danubina, 2020, 32, 84-91. | 0.4 | 2 |
| 14 | Use of pharmacogenomics in elderly patients treated for cardiovascular diseases. Croatian Medical Journal, 2020, 61, 147-158. | 0.7 | 4 |
| 15 | Association of CNR1 genotypes with changes in neurocognitive performance after eighteen-month treatment in patients with first-episode psychosis. European Psychiatry, 2019, 61, 88-96. | 0.2 | 9 |
| 16 | The lack of influence of IVS5-91 G>A polymorphism of the SCN1A gene on efficacy of lamotrigine in patients with focal epilepsy. Neurological Research, 2019, 41, 930-935. | 1.3 | 4 |
| 17 | Pharmacogenetics and the treatment of epilepsy: what do we know?. Pharmacogenomics, 2019, 20, 1093-1101. | 1.3 | 6 |
| 18 | The lack of association between COMT rs4680 polymorphism and symptomatic remission to olanzapine monotherapy in male schizophrenic patients: A longitudinal study. Psychiatry Research, 2019, 279, 389-390. | 3.3 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Lack of association of SCN2A rs17183814 polymorphism with the efficacy of lamotrigine monotherapy in patients with focal epilepsy from Herzegovina area, Bosnia and Herzegovina. Epilepsy Research, 2019, 158, 106221. | 1.6 | 6 |
| 20 | ASSOCIATION ANALYSIS OF MAOA AND SLC6A4 GENE VARIATION IN SOUTH EAST EUROPEAN WAR RELATED POSTTRAUMATIC STRESS DISORDER. Psychiatria Danubina, 2019, 31, 211-218. | 0.4 | 5 |
| 21 | GENETIC SUSCEPTIBILITY TO POSTTRAUMATIC STRESS DISORDER: ANALYSES OF THE OXYTOCIN RECEPTOR, RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR A AND CANNABINOID RECEPTOR 1 GENES. Psychiatria Danubina, 2019, 31, 219-226. | 0.4 | 19 |
| 22 | ASSOCIATIONS BETWEEN POLYMORPHISMS IN THE SOLUTE CARRIER FAMILY 6 MEMBER 3 AND THE MYELIN BASIC PROTEIN GENE AND POSTTRAUMATIC STRESS DISORDER. Psychiatria Danubina, 2019, 31, 235-240. | 0.4 | 3 |
| 23 | THE ASSOCIATION OF CATECHOL-O-METHYL-TRANSFERASE AND INTERLEUKIN 6 GENE POLYMORPHISMS WITH POSTTRAUMATIC STRESS DISORDER. Psychiatria Danubina, 2019, 31, 241-248. | 0.4 | 7 |
| 24 | ROLE OF THE ALLELIC VARIATION IN THE 5-HYDROXYTRYPTAMINE RECEPTOR 1A (HTR1A) AND THE TRYPTOPHAN HYDROXYLASE 2 (TPH2) GENES IN THE DEVELOPMENT OF PTSD. Psychiatria Danubina, 2019, 31, 256-262. | 0.4 | 5 |
| 25 | THE ROLE OF TAQI DRD2 (RS1800497) AND DRD4 VNTR POLYMORPHISMS IN POSTTRAUMATIC STRESS DISORDER (PTSD). Psychiatria Danubina, 2019, 31, 263-268. | 0.4 | 10 |
| 26 | A CANDIDATE GENE ASSOCIATION STUDY OF FKBP5 AND CRHR1 POLYMORPHISMS IN RELATION TO WAR-RELATED POSTTRAUMATIC STRESS DISORDER. Psychiatria Danubina, 2019, 31, 269-275. | 0.4 | 4 |
| 27 | Warfarin Dosing According to the Genotype-guided Algorithm is Most Beneficial in Patients With Atrial Fibrillation: A Randomized Parallel Group Trial. Therapeutic Drug Monitoring, 2018, 40, 362-368. | 2.0 | 20 |
| 28 | Monoamine Oxidase A Gene Methylation and Its Role in Posttraumatic Stress Disorder: First Evidence from the South Eastern Europe (SEE)-PTSD Study. International Journal of Neuropsychopharmacology, 2018, 21, 423-432. | 2.1 | 33 |
| 29 | Association of polymorphic variants in serotonin re-uptake transporter gene with Crohn's disease: a retrospective case-control study. Croatian Medical Journal, 2018, 59, 232-243. | 0.7 | 4 |
| 30 | Effect of antiepileptic drug comedication on lamotrigine concentrations. Croatian Medical Journal, 2018, 59, 13-19. | 0.7 | 8 |
| 31 | Characterization of ADME genes variation in Roma and 20 populations worldwide. PLoS ONE, 2018, 13, e0207671. | 2.5 | 11 |
| 32 | Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steadyâ€state disposition of lamotrigine in adults with epilepsy. British Journal of Clinical Pharmacology, 2018, 84, 2106-2119. | 2.4 | 24 |
| 33 | Rosuvastatinâ€induced Rhabdomyolysis â€“ Possible Role of Ticagrelor and Patientsâ€™ Pharmacogenetic Profile. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 509-518. | 2.5 | 22 |
| 34 | Genotype-guided warfarin dosing. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-14-20. | 0.0 | 0 |
| 35 | Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipientsâ€™ and donorsâ€™ ABCC2 gene variants, and their interactions. European Journal of Clinical Pharmacology, 2017, 73, 1129-1140. | 1.9 | 11 |
| 36 | Dapsoneâ€induced agranulocytosisâ€”possible involvement of lowâ€activity Nâ€acetyltransferase 2. Fundamental and Clinical Pharmacology, 2017, 31, 580-586. | 1.9 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population. Drug Metabolism and Personalized Therapy, 2017, 32, 11-21. | 0.6 | 27 |
| 38 | Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population. Arhiv Za Higijenu Rada I Toksikologiju, 2017, 68, 180-184. | 0.7 | 7 |
| 39 | Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study. Nordic Journal of Psychiatry, 2017, 71, 513-520. | 1.3 | 18 |
| 40 | Is there any association of apolipoprotein E gene polymorphisms with metabolic syndrome in a young population of Croatian origin?. Annals of Human Biology, 2017, 44, 287-294. | 1.0 | 1 |
| 41 | A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS ONE, 2016, 11, e0162866. | 2.5 | 96 |
| 42 | How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity / Kako polimorfizmi gena citokroma P450 utjeÄu na metabolizam i toksiÄnost ibuprofena i diklofenaka. Arhiv Za Higijenu Rada I Toksikologiju, 2016, 67, 1-8. | 0.7 | 40 |
| 43 | CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms. Pharmacogenomics, 2016, 17, 1385-1389. | 1.3 | 9 |
| 44 | Olanzapine Long-Acting Injections After Neuroleptic Malignant Syndrome. Journal of Clinical Psychopharmacology, 2016, 36, 733-735. | 1.4 | 2 |
| 45 | Clinical Application of Genotype-guided Dosing of Warfarin in Patients with Acute Stroke. Archives of Medical Research, 2015, 46, 265-273. | 3.3 | 18 |
| 46 | Erlotinib-related rhabdomyolysis: the role of pharmacogenetics and drugâ€“drug interaction. Cancer Chemotherapy and Pharmacology, 2015, 76, 1317-1319. | 2.3 | 6 |
| 47 | Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. Pharmacogenomics, 2015, 16, 137-148. | 1.3 | 47 |
| 48 | CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419. International Journal of Cardiology, 2015, 186, 282-285. | 1.7 | 6 |
| 49 | ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a caseâ€“control study. Pharmacogenomics, 2015, 16, 803-815. | 1.3 | 32 |
| 50 | VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 905-913. | 0.6 | 6 |
| 51 | Effect of Cyclosporine on Steady-State Pharmacokinetics of MPA in Renal Transplant Recipients Is Not Affected by the MPA Formulation. Therapeutic Drug Monitoring, 2014, 36, 456-464. | 2.0 | 11 |
| 52 | Treatment-resistant schizophrenia and DAT and SERT polymorphisms. Gene, 2014, 543, 125-132. | 2.2 | 33 |
| 53 | Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 â€" Implications for warfarin management and outcome in Croatian patients with acute stroke. Journal of the Neurological Sciences, 2014, 343, 30-35. | 0.6 | 5 |
| 54 | CYP2C9andABCG2polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a caseâ€“control study. Pharmacogenomics, 2013, 14, 1419-1431. | 1.3 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | The Association Study of Polymorphisms in DAT, DRD2, and COMT Genes and Acute Extrapyramidal Adverse Effects in Male Schizophrenic Patients Treated With Haloperidol. Journal of Clinical Psychopharmacology, 2013, 33, 593-599. | 1.4 | 35 |
| 56 | Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy. Collegium Antropologicum, 2013, 37, 41-5. | 0.2 | 18 |
| 57 | Association Between Lamotrigine Concentrations and ABCB1 Polymorphisms in Patients With Epilepsy. Therapeutic Drug Monitoring, 2012, 34, 518-525. | 2.0 | 40 |
| 58 | Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drugâ€“drug interaction. International Journal of Clinical Pharmacy, 2012, 34, 825-827. | 2.1 | 20 |
| 59 | Platelet serotonin in primary SjÃ¶gren's syndrome: Level and relation with disease activity. Journal of Neuroimmunology, 2012, 251, 87-89. | 2.3 | 11 |
| 60 | Adiponectin Level and Gene Variability Are Obesity and Metabolic Syndrome Markers in a Young Population. Archives of Medical Research, 2012, 43, 145-153. | 3.3 | 25 |
| 61 | Adverse drug reactions caused by drug-drug interactions reported to Croatian Agency for Medicinal Products and Medical Devices: a retrospective observational study. Croatian Medical Journal, 2011, 52, 604-614. | 0.7 | 34 |
| 62 | The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naÃ¯ve patients with first-episode schizophrenia treated with risperidone. European Journal of Clinical Pharmacology, 2010, 66, 1109-1117. | 1.9 | 80 |
| 63 | Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy. Psychiatria Danubina, 2010, 22, 335-7. | 0.4 | 10 |
| 64 | Therapeutic efficacy of acenocoumarol in a warfarin-resistant patient with deep venous thrombosis: a case report. European Journal of Clinical Pharmacology, 2009, 65, 1265-1266. | 1.9 | 3 |
| 65 | Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk. Arhiv Za Higijenu Rada I Toksikologiju, 2009, 60, 217-242. | 0.7 | 147 |
| 66 | Pharmacogenetics and interactions of antidepressants in the treatment of co-morbid illness. Psychiatria Danubina, 2009, 21, 399-400. | 0.4 | 0 |
| 67 | Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. Journal of Psychiatric Research, 2008, 42, 89-97. | 3.1 | 70 |
| 68 | The influence of 5-HT2C and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Research, 2008, 160, 308-315. | 3.3 | 55 |
| 69 | The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the bloodâ€“brain barrier in patients with generalized epilepsy. Seizure: the Journal of the British Epilepsy Association, 2008, 17, 524-530. | 2.0 | 69 |
| 70 | MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1439-1444. | 4.8 | 62 |
| 71 | Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World Journal of Biological Psychiatry, 2008, 9, 190-197. | 2.6 | 36 |
| 72 | Clinical Significance of a CYP2D6 Poor Metabolizer -A Patient With Schizophrenia on Risperidone Treatment. Therapeutic Drug Monitoring, 2008, 30, 748-751. | 2.0 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Pharamacogenetics and antidepressant treatment in integrative psychiatry perspective. Psychiatria Danubina, 2008, 20, 399-401. | 0.4 | 2 |
| 74 | Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. Journal of Psychopharmacology, 2007, 21, 728-734. | 4.0 | 37 |
| 75 | Pharmacogenetics in modern psychiatry. Psychiatria Danubina, 2007, 19, 231-3. | 0.4 | 3 |
| 76 | Serotonin transporter polymorphism in Croatian patients with major depressive disorder. Psychiatria Danubina, 2006, 18, 83-9. | 0.4 | 14 |
| 77 | Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croatian Medical Journal, 2003, 44, 425-8. | 0.7 | 70 |